A Study to Qualify [18F]MK-6240 Positron Emission Tomography (PET) for Use as a Biomarker of Neurofibrillary Tangle Pathology in Alzheimer's Disease

Trial Profile

A Study to Qualify [18F]MK-6240 Positron Emission Tomography (PET) for Use as a Biomarker of Neurofibrillary Tangle Pathology in Alzheimer's Disease

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Fluorine-18-MK 6240 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Diagnostic use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 24 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 03 Jan 2017 Status changed from recruiting to active, no longer recruiting.
    • 14 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Jan 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top